Bringing the fundamentals into focus…
Back to Royalty Pharma plc
How Royalty Pharma plc stacks up
RPRX · against 454 other Healthcare companies listed in US-listed
Growth
38/ 100
Below the middle of the pack.
Ranked #323 of 455 · scores higher than 28% of peers
Bars: peers in each 10-point band of the growth score32 peers with a growth score of 30–39, including RPRX · Click a bar to see the companies
Why growth scores 38?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings per share growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower growth in earnings per share: weaker than 76% of peers. Earnings per share growth: -19.9% vs peer median 9.8%
- slower revenue growth over three years: weaker than 64% of peers. 3-year revenue growth: 2.4% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 61% of peers. Revenue growth: 10.0% vs peer median 6.1%
Metric by metric
Position: dot = RPRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RPRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | 10.0% | 11.0% | 48% | 33% | |
| Earnings per share growthHigher is better · 171 reported | -19.9% | 21.2% | 19% | 33% | |
| 3-year revenue growthHigher is better · 433 reported | 2.4% | 11.0% | 26% | 33% |
Ranking by growth score
Top 5 and the companies ranked around RPRX| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 8.8B USD | 99 | 31 | |
| 2 | 90M USD | 99 | 27 | |
| 320 | 551M USD | 39 | 27 | |
| 320 | 36.4B USD | 39 | 50 | |
| 323 | 357M USD | 38 | 32 | |
| 323 | 578M USD | 38 | 22 | |
| 323 | 38.4B USD | 38 | 50 | |
| 323 | 191M USD | 38 | 38 | |
| 323 | 363.0B USD | 38 | 47 | |
| 328 | 10.8B USD | 37 | 41 | |
| 328 | 8.5B USD | 37 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score